Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Lands NY State Approval for Prenatal Dx Array

NEW YORK (GenomeWeb) – CombiMatrix today announced that the New York State Department of Health has approved the firm's CombiSNP Array for Prenatal Diagnosis.

The CombiSNP Array uses chromosomal microarray analysis of chorionic villi and amniocentesis samples to detect chromosomal imbalances not detected by karyotyping.

"The prenatal diagnostic test we offer is important both as a first-tier test and as a tool physicians utilize to confirm the increasing number of positive non-invasive prenatal screening results," CombiMatrix CEO Mark McDonough said in a statement.

The firm said in a statement that the American College of Obstetrics and Gynecology recommends prenatal microarray analysis when major structural fetal abnormalities are identified by ultrasound and for confirmation of positive non-invasive prenatal testing results.

McDonough added that the firm sees opportunity in the New York market and has recently hired two additional sales representatives. "We also plan to leverage the New York-based representatives of our partner, Sequenom, for prenatal diagnostic services," he said.

Irvine, California-based CombiMatrix received conditional approval from the New York State Department of Health for the CombiSNP Array for Pregnancy Loss in July 2014.